FOXP3 and cancer: In the specimens, the median and interquartile range of the percentage of Foxp3+ cells among CD3+ cells were 17.1% (11.9, 11.4–23.3%), while those in the control group without cancer were 2.6% (4.9, 1.1–6.0%) (P < 0.001).